Early Experience with Fenestrated Stent Grafts for Treatment of Juxtarenal Aortic Aneurysm

Unno, Naoki; Yamamoto, Naoto; Higashiura, Wataru; Suzuki, Minoru; Mano, Yoko; Sano, Masaki; Saito, Takaaki; Sugisawa, Ryota; Konno, Hiroyuki

doi:10.3400/avd.oa.13-00047

Cited by 6 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20] The Zenith fenestrated abdominal aortic aneurysm endovascular graft has been commercially available in the European Union since late 2005 and was approved by the Food and Drug Administration in the United States in April 2012. 21 During the development phase, our centers had the opportunity to use the device on selected patients along with a few other centers. The first procedure was performed in Malmö in 2002 and in Lille in 2004.…”

Section: Configurationmentioning

confidence: 99%

Early versus late experience in fenestrated endovascular repair for abdominal aortic aneurysm

Sveinsson

Sobocinski

Resch

et al. 2015

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Configurationmentioning

confidence: 99%

Early versus late experience in fenestrated endovascular repair for abdominal aortic aneurysm

Sveinsson

Sobocinski

Resch

et al. 2015

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…Abdominal aortic aneurysm AAA is an inflammatory cardiovascular disease common among the elderly 1,2 , and whose pathogenesis is not fully understood 1,3 . Surgical repair is currently the only option for preventing AAA rupture 4 and, notably, endovascular treatment improves the surgical outcome in AAA treatment 5,6 . Recently, we found that metabolic abnormalities, especially serum dyslipidemia, are associated with AAA progression and mortality 7,8 .…”

Section: Introductionmentioning

confidence: 99%

Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm

et al. 2018

Self Cite

View full text Add to dashboard Cite

Abdominal aortic aneurysm (AAA) is a common disease among the elderly. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been indicated as useful therapeutic tools for the treatment of cardiovascular diseases. The aim of this study was to elucidate the role of PCSK9 in the pathogenesis of AAA. We used fluorescence immunohistochemistry to assess the expression of PCSK9 in aortic tissues resected from 24 patients with AAA. Histological examination showed that PCSK9 expression in the adventitia region of the aneurysms was decreased in AAA samples. In the same region, the expression of CD36 increased. We hypothesized that CD36 expression might upregulate the transport of fatty acids into cells such as the adipocytes, and subsequently cause degradation of the adventitia in the aortic wall, contributing to AAA development.

show abstract

Early outcomes of iliac branch grafts in the endovascular repair of abdominal aortic aneurysms with concomitant bilateral common iliac artery aneurysms at a Japanese institution

et al. 2014

View full text Add to dashboard Cite

show abstract

Early Experience with Fenestrated Stent Grafts for Treatment of Juxtarenal Aortic Aneurysm

Cited by 6 publications

References 27 publications

Early versus late experience in fenestrated endovascular repair for abdominal aortic aneurysm

Early versus late experience in fenestrated endovascular repair for abdominal aortic aneurysm

Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm

Early outcomes of iliac branch grafts in the endovascular repair of abdominal aortic aneurysms with concomitant bilateral common iliac artery aneurysms at a Japanese institution

Contact Info

Product

Resources

About